Rilascio intratumorale di particelle di replicone virale (saRNA) che esprimono IL-12 nel cancro della testa e del collo
Studio delle iniezioni intratumorali di VLPONC-01 nel cancro della testa e del collo
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are:
The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)
The tumor response to IT injections of VLPONC-01
The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment
Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Cancro testa e collo
- Carcinoma a cellule squamose della testa e del collo
- Tumori solidi
- Tumore a cellule squamose della testa e del collo
- Cancro al collo della testa
- Carcinoma del cavo orale
- HNSCC
- Cavità orale
- Carcinoma a cellule squamose, testa e collo
- Tumori della testa e del collo - cellule squamose
- Carcinoma a cellule squamose della testa e del collo
- SCCHN
- SCC - Carcinoma a cellule squamose
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study is an Open label, Phase I study to determine the safety of IT injected VLPONC-01 as a therapeutic agent in subjects with non-resectable and resectable Head and Neck Cancer Squamous Cell Carcinomas (HCSCC), and secondarily to assess pathologic response and radiological response (assessed by RECIST 1.1 criteria) in the primary tumor and regional lymph nodes. Researchers also will explore tumor microenvironment changes in cytokine levels and cellular responses.
There will be three distinct cohorts enrolling sequentially:
Cohort A: Researchers will enroll unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery who will receive four doses of VLPONC-01.
Cohort C: Researchers will enroll HCSCC patients scheduled for tumor resection surgery who will receive four doses of VLPONC-1 and two doses of neoadjuvant pembrolizumab or only two doses of neoadjuvant pembrolizumab prior to tumor resection surgery.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Clinical Research Coordinator
- Numero di telefono: 650-725-9333
- Email: tpark22@stanford.edu
Luoghi di studio
-
-
California
-
Stanford, California, Stati Uniti, 34305
- Reclutamento
- Stanford University
-
Contatto:
- Clinical Research Coordinator
- Numero di telefono: 650-725-9333
- Email: tpark22@stanford.edu
-
Investigatore principale:
- Fred M Baik, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Cohort A - Unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery. With one the following prior treatments:
Subjects must have received a platinum containing chemotherapy regimen, 5-Fluorouracil chemotherapy, taxane based chemotherapy, cetuximab or gemcitabine for treatment of primary tumor in locally advanced, or metastatic settings.
Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy.
Subjects must have progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status).
Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).
Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, therefore these subjects must have been previously treated with an applicable tyrosine kinase inhibitor.
OR Cohort C - Patients with at least 1 measurable resectable lesion clinical stage I-IVb (cT1-4, N0-3) (AJCC, 8th Edition) (Amin, 2017), Histologically or cytologically confirmed HNSCC. Scheduled to undergo tumor surgical resection of the primary tumor.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and adequate bone marrow and organ function.
-
Primary tumors should be amenable to intratumoral (IT) injection >1 cm diameter. This will be determined by the Protocol Director, or the surgeon involved.
-
Subjects with either a local recurrence or a new primary tumor will be allowed.
-
Age ≥ 18 years.
-
Have acceptable organ and marrow function defined as follows:
Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 8.0 g/dL (Note: use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable) Total bilirubin ≤2x institutional upper limit of normal (ULN) AST(SGOT) or ALT(SGPT) ≤ 3.0x institutional ULN
-
Ability to understand and the willingness to provide written informed consent.
-
Life expectancy > 12 weeks (about 3 months).
-
Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria:
- Tumors which are not feasible for injections include high risk lesions that are near vital organs or important neurovascular structures, as determined by the Protocol Director or involved surgeon.
- Women of childbearing potential must have a negative serum β-hCG pregnancy test within 7 days prior to the administration of the first study treatment and/or urine pregnancy 48 hours prior to the administration of the first study treatment. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use two methods of effective contraception, one of them being a barrier method, or to abstain from sexual activity during the study and for at least 6 months after last dose of study drugs.
- Patients expected to receive other anti-cancer medication such as, chemotherapy, immunotherapy, biologic therapy, targeted therapy, monoclonal antibodies, hormonal therapy (other than leuprolide or other GnRH agonists) prior to surgery and where all acute toxicity of prior treatments have not resolved.
- Participation in another clinical study with an investigational product during the last 30 days.
- Uncontrolled intercurrent illness including, that do not respond to active medical intervention.
- Current or prior use of immunosuppressive medication within 28 days before the first dose of injection, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid.
- If applicable: Women who are breastfeeding.
- History of allogenic organ transplant that requires use of immunosuppressives.
- Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
- Any condition that, in the investigator's opinion, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
- Uncontrolled intercurrent illness including those that do not respond to active medical intervention.
- Any contraindication to the use of known history of hypersensitivity to any immune therapy's drugs.
- Subjects must not have received any live vaccine within 28 days prior to the first dose of study treatment.
- Active autoimmune disease that requires systemic therapy, in the Investigator's opinion, may increase the risk of study participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Cohort A (1 x 10^9 viral particles per injection)
Recurrent or Metastatic Head and Neck Cancer not scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly, with an additional follow-up safety visit 30 and 90 days post the final injection. |
Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01
Altri nomi:
|
|
Sperimentale: Cohort C - Group 1 (1 x 10^9 viral particles per injection plus Pembrolizumab)
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01
Altri nomi:
200mg twice 3 weeks apart IV
Altri nomi:
|
|
Sperimentale: Cohort C - Group 2 (3 x 10^8 viral particles per injection plus Pembrolizumab)
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
200mg twice 3 weeks apart IV
Altri nomi:
Weekly IT injections of 3 x 10^8 viral particles of VLPONC-01
Altri nomi:
|
|
Sperimentale: Cohort C - Pembrolizumab only
Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment. |
200mg twice 3 weeks apart IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and tolerability
Lasso di tempo: First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
To assess the safety and tolerability of VLPONC-01. Safety will be based on the occurrence of any grade 3 or higher drug-related adverse events from the VLPONC-01 injections for non-surgery patients and any grade 3 or higher drug-related adverse events that result in a delay to tumor resection surgery. |
First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Levels of circulating IL-12
Lasso di tempo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
To assess the circulating blood levels of IL-12 after VLPONC-01 treatment compared to baseline to determine the occurrence and safety profile of potential systemic inflammatory responses. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
|
|
VLPONC-01 levels in tumor tissue
Lasso di tempo: First injection to tumor resection surgery
|
To detect levels of VLPONC-01 RNA in surgically resected tissue. |
First injection to tumor resection surgery
|
|
Radiological Tumor Response
Lasso di tempo: First injection to tumor resection surgery (up to 3 months)
|
To assess the primary tumor response by RECIST. |
First injection to tumor resection surgery (up to 3 months)
|
|
Pathological Tumor Response
Lasso di tempo: First injection to tumor resection surgery (up to 3 months)
|
To assess the primary tumor response by pathological analysis. |
First injection to tumor resection surgery (up to 3 months)
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Circulating levels of cytokines, chemokines, and immune markers
Lasso di tempo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess the circulating levels cytokines, chemokines, and immune markers using a proteomics assay. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
ICH Changes in Tumor microenvironment
Lasso di tempo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess levels of CD8+ T-cells, macrophages, and other immune cell populations in surgically resected tissue compared to biopsy tissue using immunohistochemistry. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
Changes in ctDNA related to Neoadjuvant treatment
Lasso di tempo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess changes in ctDNA MRD treatment-related molecular response (Cohort C). |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
|
Changes in cellular populations
Lasso di tempo: First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
To assess the changes in cellular populations in circulating blood using flow cytometry. |
First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Fred M Baik, MD, Stanford University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Chiavetruda
- pembrolizumab
- Intratumorale
- anti-PD-1
- Iniezione informatica
- IL-12
- macrofago
- resezione tumorale
- saRNA
- Interleuchina 12
- VLP
- Particella simile a un virus
- VRP
- Particella del replicone virale
- Incapsulato VRP
- intervento chirurgico di resezione del tumore
- RNA autoamplificante
- Vaccinazioni multiple direttamente nel tumore
- particelle virali per iniezione
- particelle virali
Termini MeSH pertinenti aggiuntivi
- Malattie della bocca
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Neoplasie, cellule squamose
- Carcinoma a cellule squamose della testa e del collo
- Carcinoma, cellule squamose
- Neoplasie della testa e del collo
- Neoplasie della bocca
- pembrolizumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- VLPONC-01
- SYNERNA-01 (Altro identificatore: VLP Therapeutics, Inc.)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .